Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma
This study has been completed.
Information provided by:
National Cancer Institute (NCI)
First received: July 11, 2001
Last updated: May 14, 2011
Last verified: February 2005
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Estimated Study Completion Date:||No date given|
|Estimated Primary Completion Date:||No date given|
Fox E, Razzouk BI, Widemann BC, Xiao S, O'Brien M, Goodspeed W, Reaman GH, Blaney SM, Murgo AJ, Balis FM, Adamson PC. Phase I trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia including acute promyelocytic leukemia or lymphoma A collaborative study of The Pediatric Oncology Branch, National Cancer Institute and the Children's Oncology Group. Blood. 2007 Oct 24; [Epub ahead of print]
Fox E, Adamson PC, Murgo A, et al.: Phase 1 trial and pharmacokinetic study of arsenic trioxide in children with refractory leukemia. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-1582, 2002.